ImQuest (IQP) DuoGel Phase 1 Pharmacokinetic Study

Completed · Phase 1

Conditions studied: HIV Prevention

In brief

The purpose of this study is describe the safety and single-dose pharmacokinetics of rectally-administered IQP (ImQuest Pharmaceuticals)-0528 (DuoGel) in plasma, rectal tissue biopsies, vaginal tissue biopsies, rectal fluid and cervicovaginal fluid as well as to assess the luminal distribution of IQP-0528 in the rectum. Sixteen healthy volunteers will receive a single rectal dose of DuoGel, followed by blood, tissue and fluid sampling over the following 72 hours.

Key facts

Study ID

NCT03082690

Run by

Johns Hopkins University

People needed

10

Starts

2017-11-01

Expected to finish

2019-06-02

Last updated by the study team

2019-10-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• 18 years or older at screening
• HIV-1 negative as documented at screening
• Willing to use condoms for the duration of the study
• Willing to refrain from aspirin and non-steroidal anti-inflammatory drug (NSAID) use for one week before and after each study biopsy visit
• Available to return for all study visits
• Agrees to sexually transmitted infection (STI) reporting requirements
• Able and willing to communicate in English
• Able and willing to provide written informed consent
• Able and willing to provide adequate information for locator purposes
• Agrees not to participate in other research studies
• Willing to refrain from receptive anal intercourse and insertion of anything in the rectum for 72 hours before and after rectal biopsies.
• Additional inclusion criteria for women:
• Be pre-menopausal
• Have regular menstrual cycles (unless on contraception that causes amenorrhea or irregular menses)
• Have a negative qualitative urine pregnancy test
• Per participant report, using an effective method of contraception at enrollment; hormonal method (except vaginal ring) used continuously for the past 30 days; intrauterine device (IUD [copper or hormonal] inserted at least 30 days prior to enrollment); female sterilization; abstinent from sexual activity with male partner for the past 30 days; or sexual activity with vasectomized partner; and willingness to use effective method of contraception until the completion of final scheduled study visit if enrolled.
• Willing to refrain from insertion of anything into the vagina for at least 72 hours before and 7 days after vaginal biopsies.

You may not qualify if…

• Current known HIV-infected partners
• Current use of anticoagulant medications associated with increased risk for bleeding following mucosal biopsy (e.g., daily high dose aspirin [>81 mg], NSAIDs, or Pradaxa®)
• Current use of cytochrome P450 3A (CYP3A) inducer(s) and/or inhibitor(s)
• Use of systemic immunomodulatory medications within 4 weeks of enrollment
• Known allergic reaction to components of the study product
• History of recurrent urticaria
• Participants whose whole body radiation exposure exceeds 5000 millirem (mRem)/year.
• Participants who are currently receiving or have been on oral PrEP or PEP in the past month
• Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study or unable to comply with the study requirements.
• Significant colorectal symptom(s) as determined by medical history or by participant self-report
• Active rectal infection, requiring treatment per current Centers for Disease Control (CDC) guidelines or symptomatic urinary tract infection (UTI). Infections requiring treatment include Chlamydia (CT), gonorrhea (GC), syphilis, active herpes simplex virus (HSV) lesions, chancroid, genital sores or ulcers, and, if clinically indicated, genital warts.
• History of STI within the last 3 months.
• Use of post-exposure (PEP) or pre-exposure (PrEP) prophylaxis within the last 6 months
• History of significant gastrointestinal bleeding
• Use of any rectally administered medications within 4 weeks of enrollment or unwillingness to refrain from use of any rectally administered medications 72 hours prior to any study dosing or biopsy visit
• Use of any rectally administered products containing nonoxynol-9 (including condoms) or investigational products within 4 weeks of enrollment
• Additional exclusion criteria for women:
• Significant vaginal symptoms, genital lesions, erythema, edema or any other abnormal physical finding that, in the opinion of the investigator or designee, would contraindicate study participation.
• Active female genital tract infection, requiring treatment per current CDC guidelines or symptomatic urinary tract infection (UTI). Infections requiring treatment include Chlamydia (CT), gonorrhea (GC), syphilis, active HSV lesions, chancroid, bacterial vaginosis, vaginal candidiasis, trichomonas, genital sores or ulcers, and, if clinically indicated, genital warts.
• History of significant vaginal bleeding
• Undiagnosed irregular uterine bleeding
• Post-menopausal defined as 12 months of amenorrhea
• Per participant report, abnormalities of the female genital tract, which, in the judgment of the investigator, might increase the risk of the study to the research participant.
• Per participant report, history of cervical procedures (conization, Loop El electrosurgical Excision procedure (LEEP) procedure, cryosurgery) within the previous 6 months.
• Per participant report, use of any vaginally administered medications within 4 weeks of enrollment

Where it is running

• Johns Hopkins University — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.